Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk...

Details Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk... Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk...

2005-02-04

2010-10-19

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252160, C514S261100, C544S118000, C544S254000

Reexamination Certificate

active

07816350

ABSTRACT:
The present invention relates to a compound of formula I, or a pharmaceutically acceptable acid salt thereof.The invention further relates to the use of such compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi or protists, or Alzheimer's disease.Further aspects of the invention relate to the use of such compounds in the inhibition of cell proliferation, in the induction of apoptosis, to modulate the activity of adrenergic and/or purinergic receptors or to suppress immunostimulation. The invention also relates to the use of 2,6,9-trisubstituted 8-azapurines in maintaining mammalian ooctyes at the germinal vesicle stage.

REFERENCES:
patent: 5866702 (1999-02-01), Mackman et al.
patent: 6107301 (2000-08-01), Aldrich et al.
patent: 6458796 (2002-10-01), Haning et al.
patent: 7034032 (2006-04-01), Brown et al.
patent: 1142893 (2001-10-01), None
patent: 59-62595 (1984-04-01), None
patent: 59-062595 (1984-04-01), None
patent: WO-97/20842 (1997-06-01), None
patent: WO-97/35539 (1997-10-01), None
patent: WO-97/35846 (1997-10-01), None
patent: WO-98/28300 (1998-07-01), None
patent: WO-99/05143 (1999-02-01), None
patent: WO-99/41254 (1999-08-01), None
Baindur et. al. (J. comb. Chem., 2003, 5, 653-659).
Shealy et. al. (J. Org. Chem., 1961, 26, 4433-4440).
Ashton, Wallace T., et al., “Synthesis and Antiherpetic Activity of (±)-9[[(Z)-2- (Hydroxymethyl)cyclopropl]methyl]guanine and Related Compounds,”J. Med. Chem., vol. 31:2304-2315 (1988).
Beauchamp, Lilia M., et al., “Modifications on the Heterocyclic Base of Acyclovir: Syntheses and Antiviral Properties,”J. Med. Chem., vol. 28:982-987 (1985).
Chorvat, Robert J., et al., “Synthesis Corticotropin-Releasing Factor Receptor Binding Affinity, and Pharmacokinetic Properties of Triazolo-, and Pyrrolopyrimidines and -pyridines,”J. Med. Chem., vol. 42:833-848 (1999).
Shealy, Y. Fulmer, et al., “ν-Triazolo[4,5-d]pyrimidines. I. Synthesis and Nucleophilic Substitution of 7- Chloro Derivatives of 3-Substituted ν-Triazolo[4,5-d]pyrimidines,”The Kettering-Meyer Laboratory, Southern Research Institute, (1961).
Shealy, Y. Fulmer, et al., “ν-Triazolo[4,5-d]pyrimidines. III. N-(3-Alkyl-5-amino-3H-ν-triazolo[4,5-d ]pyrimidin-7-yl) -amino Acids,”Kettering-Meyer Laboratory, Southern Reserach Institute, (1966).

Affiliated with

Also associated with

Rating

Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4225797